Form 4: Director Olivier Brandicourt Receives Alnylam Equity Grant
Statement of Changes in Beneficial Ownership
Alnylam Pharmaceuticals director Olivier Brandicourt was granted 671 restricted stock units and 1,441 stock options as part of annual compensation.
Summary
- Director Olivier Brandicourt acquired 671 restricted stock units (RSUs) on May 20, 2026.
- The director was also granted 1,441 stock options with an exercise price of $298.48.
- Both the RSUs and stock options vest in full on the earlier of the first anniversary of the grant date or the director's retirement/resignation (within 90 days of the anniversary).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no material impact on company operations or financial health.
Positives
- Alignment of director interests with long-term shareholder value through equity-based compensation.
Negatives
- Dilutive impact of new equity grants, though minimal in scale.
Risks
- Market volatility affecting the value of the granted stock options.
- Potential for future dilution if additional equity incentives are issued to board members.
Future Outlook
The equity grants are subject to standard vesting schedules tied to the director's continued service or retirement timeline.
Industry Context
StockSavvy.ai notes that equity grants to non-employee directors are standard practice in the biotechnology sector to ensure board alignment with corporate performance and long-term strategic goals.
Comparison to Industry Standards
- The grant structure follows standard industry practices for board compensation in mid-to-large cap pharmaceutical companies.
- Vesting periods of one year are consistent with typical director compensation packages at peer firms like Ionis Pharmaceuticals or Vertex Pharmaceuticals.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Equity Compensation | Grant of RSUs and stock options to director under the 2018 Stock Incentive Plan. | 05/20/2026 | Standard alignment of director incentives. |
Stakeholder Impact
- Minor dilution for existing shareholders due to the issuance of new equity.
Next Steps
- Vesting of equity grants on May 20, 2027.
Key Dates
| Date | Description |
|---|---|
| 05/20/2026 | Date of grant for RSUs and stock options. |
| 05/20/2027 | Vesting date for stock options and RSUs. |
| 05/20/2036 | Expiration date for stock options. |
Keywords
Alnylam Pharmaceuticals, ALNY, Form 4, Insider Trading, Equity Compensation, Director Compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.